nach oben

Erschienen in:

03.10.2014 | Zertifizierte Fortbildung

Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?

MRT, PET und SPECT

verfasst von: Monique Sakretz, Dr.-Ing. Jens Kurth, Prof. Dr. med. Stefan Teipel, Prof. Dr. med. Bernd Joachim Krause

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 10/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Morphologische, funktionelle und molekulare bildgebende Verfahren erfahren einen wachsenden Stellenwert in der Demenzdiagnostik. Vor allem in der differenzialdiagnostischen Einordnung der zugrunde liegenden Erkrankung und ihrer Abgrenzung gegenüber potenziell reversiblen somatischenoder neuropsychiatrischen Ursachen einer demenziellen Entwicklung finden sie klinische Anwendung.

Bickel H. Epidemiologie und Gesundheitsökonomie. In: Wallesch CW, Förstl H (Hrsg) Demenzen. Referenzreihe Neurologie. Thieme Verlag, Stuttgart. 2005;S 1–15.

Prince M, Bryce R, Albanese E, Wimo A, Ribeiro W, Ferri CP. The global prevalence of dementia: a systematic review and metaanalysis. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2013;9(1):63–75 e2.CrossRef

Buschert VC, Giegling I, Teipel SJ, Jolk S, Hampel H, Rujescu D, et al. Long-term observation of a multicomponent cognitive intervention in mild cognitive impairment. J Clin Psychiatry. 2012;73(12):e1492–1498.CrossRef

WHO, Dilling H, Mombour W, et al.: Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F), Klinisch-diagnostische Leitlinien. 6. Aufl. Bern, Huber 2008.

Hardy J. The amyloid hypothesis for Alzheimer’s disease: a critical reappraisal. J Neurochem. 2009;110(4):1129–1134.PubMedCrossRef

Jack CR, Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology. 2012;263(2):344–361.PubMedPubMedCentralCrossRef

Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, et al. A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline. Nature. 2012;488(7409):96–99.PubMedCrossRef

Jack CR, Jr., Knopman DS, Jagus WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade. Lancet Neurol. 2010;9(1):119–128.PubMedPubMedCentralCrossRef

Jack CR, Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer’s disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207–216.PubMedPubMedCentralCrossRef

10.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):280–92.PubMedPubMedCentralCrossRef

11.

Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):270–279.PubMedPubMedCentralCrossRef

12.

Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke. 2006;37(9):2220–2241.PubMedCrossRef

13.

Gold G, Kovari E, Herrmann FR, Canuto A, Hof PR, Michel JP, et al. Cognitive consequences of thalamic, basal ganglia, and deep white matter lacunes in brain aging and dementia. Stroke. 2005;36(6):1184–1188.PubMedCrossRef

14.

Brown WR, Moody DM, Thore CR, Challa VR, Anstrom JA. Vascular dementia in leukoaraiosis may be a consequence of capillary loss not only in the lesions, but in normal-appearing white matter and cortex as well. J Neurol Sci. 2007;257(1-2):62–66.PubMedPubMedCentralCrossRef

15.

Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, et al. Microvascular injury and blood-brain barrier leakage in Alzheimer’s disease. Neurobiol Aging. 2007;28(7):977–986.PubMedCrossRef

16.

Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology. 1998;51(6):1546–1554.PubMedCrossRef

17.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12):1863–1872.PubMedCrossRef

18.

Gifford DR, Holloway RG, Vickrey BG. Systematic review of clinical prediction rules for neuroimaging in the evaluation of dementia. Archives of internal medicine. 2000;160(18):2855–2862.PubMedCrossRef

19.

Dickerson BC, Goncharova I, Sullivan MP, Forchetti C, Wilson RS, Bennett DA, et al. MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease. Neurobiol Aging. 2001;22(5):747–754.PubMedCrossRef

20.

Devanand DP, Liu X, Tabert MH, Pradhaban G, Cuasay K, Bell K, et al. Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer’s disease. Biol Psychiatry. 2008;64(10):871–879.PubMedPubMedCentralCrossRef

21.

Teipel SJ, Bokde AL, Born C, Meindl T, Reiser M, Möller HJ, et al. Morphological substrate of face matching in healthy ageing and mild cognitive impairment: a combined MRI-fMRI study. Brain. 2007;130(Pt 7):1745–1758.PubMedCrossRef

22.

Bokde AL, Karmann M, Teipel SJ, Born C, Lieb M, Reiser MF, et al. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study. J Clin Psychopharmacol. 2009;29(2):147–156.PubMedCrossRef

23.

Meindl T, Teipel S, Elmouden R, Mueller S, Koch W, Dietrich O, et al. Test-retest reproducibility of the default-mode network in healthy individuals. Human brain mapping.31(2):237-246.

24.

Koch W, Teipel S, Mueller S, Benninghoff J, Wagner M, Bokde AL, et al. Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer’s disease. Neurobiology of aging. 2012;33(3):466–478.PubMedCrossRef

25.

Mosconi L, Tsui WH, Herholz K, Pupi A, Drzezga A, Lucignani G, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 2008;49(3):390–398.CrossRef

26.

Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, Modat M, et al. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer’s disease. J Alzheimers Dis. 2010;20(2):587–598.PubMed

27.

Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol. 1997;42(1):85–94.PubMedCrossRef

28.

Bohnen NI, Djang DS, Herholz K, Anzai Y, Minoshima S. Effectiveness and safety of 18F-FDG PET in the evaluation of dementia: a review of the recent literature. J Nucl Med. 2012;53(1):59–71.PubMedCrossRef

29.

Foster NL, Heidebrink JL, Clark CM, Jagust WJ, Arnold SE, Barbas NR, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain. 2007;130(Pt 10):2616–2635.PubMedCrossRef

30.

Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine. 1995;36(7):1238–1248.

31.

Quigley H, Colloby SJ, O’Brien JT. PET imaging of brain amyloid in dementia: a review. Int J Geriatr Psychiatry. 2011;26(10):991–999.PubMedCrossRef

32.

McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2011;7(3):263–269.CrossRef

33.

Pimlott SL, Ebmeier KP. SPECT imaging in dementia. Br J Radiol. 2007;80 Spec No 2:S153–159.CrossRef

34.

Risacher SL, Saykin AJ, West JD, Shen L, Firpi HA, McDonald BC. Baseline MRI predictors of conversion from MCI to probable AD in the ADNI cohort. Curr Alzheimer Res. 2009;6(4):347–361.PubMedPubMedCentralCrossRef

35.

Jack CR, Jr., Petersen RC, Xu YC, O’Brien PC, Smith GE, Ivnik RJ, et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology. 1999;52(7):1397–1403.PubMedPubMedCentralCrossRef

36.

Barnes J, Bartlett JW, van de Pol LA, Loy CT, Scahill RI, Frost C, et al. A meta-analysis of hippocampal atrophy rates in Alzheimer’s disease. Neurobiol Aging. 2009;30(11):1711–1723.PubMedPubMedCentralCrossRef

37.

Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol. 1993;33(6):403–408.PubMedCrossRef

38.

Scheltens P, Leys D, Barkhof F, Huglo D, Weinstein HC, Vermersch P, et al. Atrophy of medial temporal lobes on MRI in „probable“ Alzheimer’s disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967–972.PubMedPubMedCentralCrossRef

39.

Duara R, Loewenstein DA, Potter E, Appel J, Greig MT, Urs R, et al. Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease. Neurology. 2008;71(24):1986–1992.PubMedPubMedCentralCrossRef

40.

Burton EJ, Barber R, Mukaetova-Ladinska EB, Robson J, Perry RH, Jaros E, et al. Medial temporal lobe atrophy on MRI differentiates Alzheimer’s disease from dementia with Lewy bodies and vascular cognitive impairment: a prospective study with pathological verification of diagnosis. Brain. 2009;132(Pt 1):195–203.PubMedCrossRef

41.

Jack CR, Jr., Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, et al. Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative. Alzheimers Dement. 2010;6(3):212–220.PubMedPubMedCentralCrossRef

42.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The Alzheimer’s Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement. 2013;9(5):e111–194.CrossRef

43.

Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, et al. Cerebral amyloid angiopathy in the brains of patients with Alzheimer’s disease: the CERAD experience, Part XV. Neurology. 1996;46(6):1592–1596.PubMedCrossRef

44.

Herholz K, Nordberg A, Salmon E, Perani D, Kessler J, Mielke R, et al. Impairment of neocortical metabolism predicts progression in Alzheimer’s disease. Dement Geriatr Cogn Disord. 1999;10(6):494–504.PubMedCrossRef

45.

Bloudek LM, Spackman DE, Blankenburg M, Sullivan SD. Review and meta-analysis of biomarkers and diagnostic imaging in Alzheimer’s disease. J Alzheimers Dis. 2011;26(4):627–645.PubMed

46.

Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol. 9. England: Copyright (c) 2010 Elsevier Ltd. All rights reserved.; 2010. p. 1118–1127.PubMedCrossRef

47.

Yeo JM, Lim X, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci. 2013;263(7):539–552.PubMedCrossRef

48.

Rabinovici GD, Jagust WJ. Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol. 2009;21(1):117–128.PubMedPubMedCentralCrossRef

49.

Cairns NJ, Ikonomovic MD, Benzinger T, Storandt M, Fagan AM, Shah AR, et al. Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol. 2009;66(12):1557–1562.PubMedPubMedCentralCrossRef

50.

Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. Arch Neurol. 2001;58(12):1985–1992.PubMedCrossRef

51.

Valkanova V, Ebmeier KP. Neuroimaging in dementia. Maturitas. 2014.

52.

Heiss WD, Zimmermann-Meinzingen S. PET imaging in the differential diagnosis of vascular dementia. J Neurol Sci. 2012;322(1-2):268–273.PubMedCrossRef

53.

Rosen HJ, Gorno-Tempini ML, Goldman WP, Perry RJ, Schuff N, Weiner M, et al. Patterns of brain atrophy in frontotemporal dementia and semantic dementia. Neurology. 2002;58(2):198–208.PubMedCrossRef

54.

Boccardi M, Laakso MP, Bresciani L, Galluzzi S, Geroldi C, Beltramello A, et al. The MRI pattern of frontal and temporal brain atrophy in fronto-temporal dementia. Neurobiol Aging. 2003;24(1):95–103.PubMedCrossRef

55.

Frisoni GB. Structural imaging in the clinical diagnosis of Alzheimer’s disease: problems and tools. J Neurol Neurosurg Psychiatry. 2001;70(6):711–718.PubMedPubMedCentralCrossRef

56.

Lojkowska W, Ryglewicz D, Jedrzejczak T, Sienkiewicz-Jarosz H, Minc S, Jakubowska T, et al. SPECT as a diagnostic test in the investigation of dementia. J Neurol Sci. 2002;203–204:215-9.

57.

Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry. 2004;12(6):554–570.PubMedCrossRef

58.

McMurtray AM, Chen AK, Shapira JS, Chow TW, Mishkin F, Miller BL, et al. Variations in regional SPECT hypoperfusion and clinical features in frontotemporal dementia. Neurology. 2006;66(4):517–522.PubMedCrossRef

59.

Gorno-Tempini ML, Dronkers NF, Rankin KP, Ogar JM, Phengrasamy L, Rosen HJ, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55(3):335–346.PubMedPubMedCentralCrossRef

60.

Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, Hodges JR. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. Brain. 2003;126(Pt 11):2406–2418.PubMedCrossRef

61.

Borroni B, Grassi M, Agosti C, Paghera B, Alberici A, Di Luca M, et al. Latent profile analysis in frontotemporal lobar degeneration and related disorders: clinical presentation and SPECT functional correlates. BMC Neurol. 2007;7:9.

62.

Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Abeta amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388–401.PubMedPubMedCentralCrossRef

63.

Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Perneczky R, Forstl H, et al. Longitudinal changes of cerebral glucose metabolism in semantic dementia. Dement Geriatr Cogn Disord. 2006;22(4):346–351.PubMedCrossRef

64.

Whitwell JL, Weigand SD, Shiung MM, Boeve BF, Ferman TJ, Smith GE, et al. Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer’s disease. Brain. 2007;130(Pt 3):708–719.PubMedPubMedCentralCrossRef

65.

Vemuri P, Simon G, Kantarci K, Whitwell JL, Senjem ML, Przybelski SA, et al. Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. Neuroimage. 2011;55(2):522–531.PubMedPubMedCentralCrossRef

66.

Kantarci K, Ferman TJ, Boeve BF, Weigand SD, Przybelski S, Vemuri P, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology. 2012;79(6):553–560.PubMedPubMedCentralCrossRef

67.

Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. Journal of neurology, neurosurgery, and psychiatry. 2007;78(11):1176–1181.PubMedPubMedCentralCrossRef

68.

Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of (1)(2)(3)I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Parkinsonism Relat Disord. 2012;18(3):225–229.PubMedCrossRef

69.

Shattuck DW, Joshi AA, Pantazis D, Kan E, Dutton RA, Sowell ER, et al. Semi-automated method for delineation of landmarks on models of the cerebral cortex. Journal of neuroscience methods. 2009;178(2):385–392.PubMedPubMedCentralCrossRef

70.

Ashburner J, Friston KJ. Unified segmentation. NeuroImage. 2005;26(3):839–851.PubMedCrossRef

71.

Dyrba M, Ewers M, Wegrzyn M, Kilimann I, Plant C, Oswald A, et al. Robust automated detection of microstructural white matter degeneration in Alzheimer’s disease using machine learning classification of multicenter DTI data. PloS one. 2013;8(5):e64925.CrossRef

72.

Chien DT, Bahri S, Szardenings AK, Walsh JC, Mu F, Su MY, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. Journal of Alzheimer’s disease: JAD. 2013;34(2):457–468.PubMed

73.

Chien DT, Szardenings AK, Bahri S, Walsh JC, Mu F, Xia C, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F18]-T808. Journal of Alzheimer’s disease: JAD. 2014;38(1):171–184.PubMed

Titel: Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?
MRT, PET und SPECT
verfasst von: Monique Sakretz
Dr.-Ing. Jens Kurth
Prof. Dr. med. Stefan Teipel
Prof. Dr. med. Bernd Joachim Krause
Publikationsdatum: 03.10.2014
Verlag: Urban & Vogel
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 10/2014
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-014-0811-0

Neu in den Fachgebieten Neurologie und Psychiatrie

23.04.2024 | Demenz | Nachrichten

Springer Medizin

Welche bildgebenden Verfahren sind in der Demenzdiagnostik sinnvoll?

MRT, PET und SPECT

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2014

„Nicht schneller, sondern anders arbeiten“

Plant die Koalition ein Klinik-„Reförmchen“?

Informationen zu Targin für Ärzte und Patienten

Neu: Beschwerdeportal für IGeL-Missstände

Brauchen wir eine neue Subtypisierung?

Demenzrisiko erkennen

Neu in den Fachgebieten Neurologie und Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein